Celmatix Inc.
NEW YORK, NY · Founded 2010 · CIK 0001514000 · Biotech · Private
Small molecule and antibody therapeutics for women's health including FSH receptor agonist, JNK inhibitor, and AMH-targeting antibodies
celmatix.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $20M
- 6 Form D · Apr 2016
- 126 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 4 granted · 36 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2010201120122013201420152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $806,129 | |
| Private capital raised | Form D · SEC | $1,499,997 | |
| Private capital raised | Form D · SEC | $4,012,850 | |
| Private capital raised | Form D · SEC | $5,510,000 | |
| Private capital raised | Form D · SEC | $3,757,754 | |
| Private capital raised | Form D · SEC | $4,799,999 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2499 | Trex Bio | — | — |
| 2500 | Emergent BioSolutions | — | $48M |
| 2501 | ARTELO BIOSCIENCES, INC. | — | $33M |
| 2502 | Celmatix Inc. | — | $20M |
| 2503 | Exciva | — | — |
| 2504 | GYRE THERAPEUTICS, INC. | — | $5.0M |
| 2505 | VIVOVERSE, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Laura BandakDirector · Executive Officer
- Piraye BeimDirector · Executive Officer
- Steven WinickDirector
Patents
- Compositions And Methods For Peripheral Targeting Of Melatonin Receptor Agonistapplication
- Methods And Systems For Assessing Infertility As A Result Of Declining Ovarian Reserve And Functionapplication
- Systems And Methods For Determining The Probability Of A Pregnancy At A Selected Point In Timegranted
- Methods And Systems For Assessing Infertility And Related Pathologiesapplication
- Methods For Assessing The Probability Of Achieving Ongoing Pregnancy And Informing Treatment Therefromapplication
- Systems And Methods For Non-hormonal Female Contraceptive Drug Target Identification And Prioritizationapplication
- Methods For Assessing Risk Of Increased Time-to-first-conceptionapplication
- Systems And Methods For Determining The Probability Of A Pregnancy At A Selected Point In Timeapplication
- Measurement System And Method For Defining And Determining An Ovarian Reserveapplication
- Methods For Assessing The Potential For Reproductive Success And Informing Treatment Therefromapplication
- Methods And Systems For Assessing Infertility And Related Pathologiesgranted
- System And Method For Processing Electronic Medical And Genetic/genomic Information Using Machine Learning And Other Advanced Analytics Techniquesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.